Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED95 of remimazolam for loss of consciousness with remifentanil in the elderly
KCT0011645Phase 4Not yet recruiting
- Sponsor
- Hanlim Pharm
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of remimazolam, sponsored by Hanlim Pharm. Primary endpoint: ED95 for loss of consciousness with remimazolam plus remifentanil. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on KCT0011645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011645.